Investment House LLC raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 1.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 49,072 shares of the medical research company’s stock after buying an additional 485 shares during the quarter. Investment House LLC’s holdings in Amgen were worth $11,283,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in the business. Sequoia Financial Advisors LLC grew its holdings in shares of Amgen by 4.2% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 9,680 shares of the medical research company’s stock worth $2,283,000 after purchasing an additional 387 shares during the last quarter. Orion Portfolio Solutions LLC grew its holdings in shares of Amgen by 7.4% in the 2nd quarter. Orion Portfolio Solutions LLC now owns 6,363 shares of the medical research company’s stock worth $1,501,000 after purchasing an additional 436 shares during the last quarter. Asset Dedication LLC grew its holdings in shares of Amgen by 3.8% in the 2nd quarter. Asset Dedication LLC now owns 6,292 shares of the medical research company’s stock worth $1,481,000 after purchasing an additional 231 shares during the last quarter. Stephens Inc. AR grew its holdings in shares of Amgen by 2.9% in the 2nd quarter. Stephens Inc. AR now owns 35,997 shares of the medical research company’s stock worth $8,490,000 after purchasing an additional 1,007 shares during the last quarter. Finally, Nuveen Asset Management LLC grew its holdings in shares of Amgen by 4.4% in the 2nd quarter. Nuveen Asset Management LLC now owns 3,901,641 shares of the medical research company’s stock worth $920,241,000 after purchasing an additional 166,076 shares during the last quarter. 75.23% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Amgen stock traded up $1.15 on Wednesday, reaching $237.74. The stock had a trading volume of 1,410,746 shares, compared to its average volume of 2,534,906. Amgen Inc. has a 1 year low of $177.05 and a 1 year high of $264.97. The company has a market cap of $138.40 billion, a P/E ratio of 19.18, a price-to-earnings-growth ratio of 1.85 and a beta of 0.76. The company has a current ratio of 2.28, a quick ratio of 1.88 and a debt-to-equity ratio of 3.12. The business’s 50 day moving average is $227.94 and its two-hundred day moving average is $238.44.
The company also recently declared a quarterly dividend, which will be paid on Monday, March 8th. Stockholders of record on Monday, February 15th will be issued a $1.76 dividend. This represents a $7.04 dividend on an annualized basis and a dividend yield of 2.96%. This is an increase from Amgen’s previous quarterly dividend of $1.60. The ex-dividend date is Thursday, February 11th. Amgen’s dividend payout ratio is presently 43.18%.
In related news, Director R Sanders Williams sold 250 shares of the firm’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $242.40, for a total value of $60,600.00. Following the sale, the director now directly owns 4,909 shares of the company’s stock, valued at $1,189,941.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.36% of the company’s stock.
A number of equities research analysts have commented on the stock. Daiwa Capital Markets assumed coverage on shares of Amgen in a report on Tuesday, December 29th. They set a “buy” rating and a $300.00 price objective on the stock. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Amgen in a report on Sunday, December 27th. Oppenheimer initiated coverage on shares of Amgen in a report on Sunday, December 27th. They issued a “buy” rating and a $266.00 price target for the company. The Goldman Sachs Group lowered shares of Amgen from a “conviction-buy” rating to a “buy” rating in a report on Tuesday, December 15th. Finally, Cantor Fitzgerald reduced their price objective on shares of Amgen from $279.00 to $278.00 and set an “overweight” rating for the company in a research note on Thursday, October 29th. Three research analysts have rated the stock with a sell rating, twelve have given a hold rating and eighteen have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $254.92.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease.
Further Reading: How much can an individual set aside as a catch-up contribution?
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.